Antiviral treatment with fluoxetine for rituximab-associated chronic echovirus 13 meningoencephalitis and myofasciitis.
enterovirus
fluoxetine
hypogammaglobulinaemia
intravenous immunoglobulins
meningoencephalitis
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
23
05
2022
received:
08
03
2022
accepted:
04
06
2022
pubmed:
29
6
2022
medline:
11
9
2022
entrez:
28
6
2022
Statut:
ppublish
Résumé
Enterovirus infections pose a serious threat for patients with humoral deficiencies and may be lethal, whilst the efficacy of proposed treatment options such as corticosteroids, intravenous immunoglobulins and fluoxetine remains debated. Viral clearance was investigated in a patient with rituximab-induced B-cell depletion and chronic echovirus 13 (E13) meningoencephalitis/myofasciitis in response to intravenous immunoglobulins and fluoxetine using sequential semi-quantitative E13 viral load measurements by real-time reverse transcription polymerase chain reaction. Fluoxetine concentrations in plasma and cerebrospinal fluid were determined by liquid chromatography mass spectrometry. Intravenous immunoglobulins appeared ineffective in this case of E13 infection, whereas virus clearance in cerebrospinal fluid was obtained after 167 days of oral fluoxetine. Since treatment with corticosteroids resulted in a flare of symptoms, rechallenge with viral load measurements was not attempted. In this report of a patient with rituximab-associated chronic echovirus 13 meningoencephalitis, viral clearance in response to single treatment options is assessed for the first time. Our observations further support the in vivo efficacy of fluoxetine against enteroviral infections. More research is needed to establish its efficacy in different enterovirus strains.
Sections du résumé
BACKGROUND AND PURPOSE
Enterovirus infections pose a serious threat for patients with humoral deficiencies and may be lethal, whilst the efficacy of proposed treatment options such as corticosteroids, intravenous immunoglobulins and fluoxetine remains debated.
METHODS
Viral clearance was investigated in a patient with rituximab-induced B-cell depletion and chronic echovirus 13 (E13) meningoencephalitis/myofasciitis in response to intravenous immunoglobulins and fluoxetine using sequential semi-quantitative E13 viral load measurements by real-time reverse transcription polymerase chain reaction. Fluoxetine concentrations in plasma and cerebrospinal fluid were determined by liquid chromatography mass spectrometry.
RESULTS
Intravenous immunoglobulins appeared ineffective in this case of E13 infection, whereas virus clearance in cerebrospinal fluid was obtained after 167 days of oral fluoxetine. Since treatment with corticosteroids resulted in a flare of symptoms, rechallenge with viral load measurements was not attempted.
CONCLUSION
In this report of a patient with rituximab-associated chronic echovirus 13 meningoencephalitis, viral clearance in response to single treatment options is assessed for the first time. Our observations further support the in vivo efficacy of fluoxetine against enteroviral infections. More research is needed to establish its efficacy in different enterovirus strains.
Substances chimiques
Antiviral Agents
0
Immunoglobulins, Intravenous
0
Fluoxetine
01K63SUP8D
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3117-3123Informations de copyright
© 2022 European Academy of Neurology.
Références
Bauer L, Manganaro R, Zonsics B, et al. Fluoxetine inhibits enterovirus replication by targeting the viral 2C protein in a stereospecific manner. ACS Infecti Dis. 2019;5(9):1609-1623. doi:10.1021/acsinfecdis.9b00179
Maillet F, Pineton De Chambrun M, Monzani Q, et al. Enteroviral infections in adults treated with rituximab: a new case of chronic meningitis and myofasciitis and literature review. Revue de Medecine Interne. 2020;41(3):200-205. doi:10.1016/j.revmed.2019.12.018
Duléry R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after COVID-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96(8):934-944. doi:10.1002/AJH.26209
Betrains A, Godinas L, Woei-A-Jin FJSH, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021;192(6):1100-1105. doi:10.1111/bjh.17266
Wagner JN, Leibetseder A, Troescher A, Panholzer J, von Oertzen TJ. Efficacy and safety of intravenous immunoglobulins for the treatment of viral encephalitis: a systematic literature review. J Neurol. 2022;269(2):712-724. doi:10.1007/S00415-021-10494-W
Hurdiss DL, el Kazzi P, Bauer L, et al. Fluoxetine targets an allosteric site in the enterovirus 2C AAA+ ATPase and stabilizes a ring-shaped hexameric complex. Sci Adv. 2022;8(1):eabj7615. doi:10.1126/SCIADV.ABJ7615
Gofshteyn J, Cárdenas AM, Bearden D. Treatment of chronic enterovirus encephalitis with fluoxetine in a patient with X-linked agammaglobulinemia. Pediatr Neurol. 2016;64:94-98. doi:10.1016/j.pediatrneurol.2016.06.014
Kapadia RK, Gill CM, Baca C, et al. Enterovirus A71 causing meningoencephalitis and acute flaccid myelitis in a patient receiving rituximab. J Neuroimmunol. 2021;358:577639. doi:10.1016/J.JNEUROIM.2021.577639
Sham L, Bitnun A, Branson H, et al. Treatment of rituximab-associated chronic CNS enterovirus using IVIg and fluoxetine. Neurology. 2019;92(19):916-918. doi:10.1212/WNL.0000000000007468
Committee for Medicinal Products for Human Use (European Medicines Agency). Guideline on Bioanalytical Method Validation. EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2. 2011. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf
Engelhart DA, Jenkins AJ. Comparison of drug concentrations in postmortem cerebrospinal fluid and blood specimens. J Anal Toxicol. 2007;31(9):581-587. doi:10.1093/jat/31.9.581
Renshaw PF, Guimaraes AR, Fava M, et al. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry. 1992;149(11):1592-1594. doi:10.1176/ajp.149.11.1592
Cheng HY, Huang YC, Yen TY, et al. The correlation between the presence of viremia and clinical severity in patients with enterovirus 71 infection: a multi-center cohort study. BMC Infect Dis. 2014;14(1):417. doi:10.1186/1471-2334-14-417
Planitzer CB, Farcet MR, Schiff RI, Ochs HD, Kreil TR. Neutralization of different echovirus serotypes by individual lots of intravenous immunoglobulin. J Med Virol. 2011;83(2):305-310. doi:10.1002/jmv.21980
Zampieri S, Ghirardello A, Iaccarino L, et al. Polymyositis-dermatomyositis and infections. Autoimmunity. 2006;39(3):191-196. doi:10.1080/08916930600622348
van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317. doi:10.1038/SJ.LEU.2403202